On Thursday, Becton, Dickinson and Co. (NYSE:BDX)’s shares declined -0.52% to $135.20.
CareFusion, a BD company (BDX), declares that its enterprise-level Pyxis® ES platform, developed to assist hospitals and health systems better manage medications across the care continuum, is now live in more than 600 sites.
“Over the past couple of years, there has been noticeable acceleration in the adoption of enterprise-level technology for automated medication dispensing, motivating health care facilities to upgrade from existing Pyxis technology or an alternative approach to dispensing,” said Jason Strohm, worldwide vice president and general manager of Dispensing and Preparation Technologies for BD. “The Pyxis ES platform provides enterprise-level medication administration that assists improve medication safety and inventory administration, while making it easier for clinicians to optimize their time toward providing care.”
A recent TechValidate survey of about 100 hospital pharmacists presently running on the Pyxis ES platform reveals the ways in which using the Pyxis ES platform provides value within and across the integrated health care delivery network as compared to traditional cart filling methods or other technology solutions.
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Life Sciences segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers.
Crestwood Equity Partners LP (NYSE:CEQP)’s shares dropped -4.68% to $2.65.
Crestwood Equity Partners LP (CEQP) (“Crestwood Equity”) and Crestwood Midstream Partners LP (CMLP) (“Crestwood Midstream”) declared recently that Crestwood Equity’s Registration Statement on Form S-4 has been declared effective by the Securities and Exchange Commission (“SEC”), and that Crestwood Midstream has filed a proxy statement with the SEC. Crestwood Midstream will hold a special meeting for its unitholders to vote on proposals related to the merger on September 30, 2015 at 10:00 a.m. Central Time, at 700 Louisiana Street, Suite 2550, Houston, TX 77002.
Crestwood Midstream unitholders of record at the close of business on August 24, 2015, will be entitled to receive notice of and to vote at the special meeting, and Crestwood Midstream will commence mailing proxy materials to its unitholders on or about September 1, 2015. At the special meeting, Crestwood Midstream unitholders will meet to (i) consider and vote upon the approval of the Agreement and Plan of Merger dated as of May 5, 2015, by and among Crestwood Equity, Crestwood Equity GP LLC, CEQP ST SUB LLC, MGP GP, LLC, Crestwood Midstream Holdings LP, Crestwood Midstream, Crestwood Midstream GP LLC, and Crestwood Gas Services GP LLC, as it may be amended from time to time, and the merger transactions contemplated thereby; (ii) consider and vote upon the approval of the proposal to adjourn the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve the merger agreement; and (iii) transact such other business as may properly be presented at the meeting or any adjournments or postponements of the meeting.
Crestwood Equity Partners LP provides midstream solutions to customers in the crude oil, natural gas liquids (NGLs), and natural gas sectors of the energy industry in the United States. It operates through three segments: Gathering and Processing; Storage and Transportation; and NGL and Crude Services. The Gathering and Processing segment engages in the gathering, processing, treating, compression, transportation, and sale of natural gas; and the delivery of natural gas liquids to producers in unconventional shale plays and tight-gas plays in West Virginia, Wyoming, Texas, Arkansas, New Mexico, and Louisiana.
At the end of Thursday’s trade, American Homes 4 Rent (NYSE:AMH)‘s shares dipped -0.58% to $15.56.
American Homes 4 Rent (AMH) a leading provider of high quality single-family homes for rent, declared recently that the Company will make a presentation at the Bank of America Merrill Lynch 2015 Global Real Estate Conference in New York at the Westin Times Square on Thursday, September 17, 2015, startning at 3:30 p.m. Eastern Time. The presentation will be webcast and will be accessible on the Company’s website at www.americanhomes4rent.com under the For Investors tab on the day of the conference. A replay of the webcast will be accessible through October 1, 2015.
American Homes 4 Rent is a real estate investment trust. The firm engages in the acquisition, renovation, leasing, and operating single-family home rental properties in the United States. American Homes 4 Rent was founded in 2012 and is based in Malibu, California.
Advaxis, Inc. (NASDAQ:ADXS), ended its Thursday’s trading session with 15.15% gain, and closed at $15.96.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, declared that the Farrah Fawcett Foundation honored Advaxis with the Foundation’s inaugural “Medical Visionary Angel Award” on September 9, 2015, at the Wallis Annenberg Center for the Performing Arts in Beverly Hills, Calif. The event benefitted the Farrah Fawcett Foundation / Stand Up To Cancer (SU2C) research team on HPV-related cancers and celebrated the life and legacy of actress Farrah Fawcett and her commitment to fund research for a cure for anal cancer, which took her life in 2009.
Advaxis also declared plans to commence enrollment this fall of a Phase 2 clinical study of Advaxis’s lead investigational Lm Technology(TM) immunotherapy, axalimogene filolisbac (ADXS-HPV), in metastatic anal cancer. The study is to be called FAWCETT (Fighting Anal-Cancer with CTL Enhancing Tumor Therapy), in honor of Farrah Fawcett, and will be the company’s second Phase 2 study of axalimogene filolisbac in anal cancer. The two-part, single-arm, open-label study is designed to evaluate the efficacy and safety of axalimogene filolisbac as monotherapy in patients with human papillomavirus (HPV)-associated metastatic anal cancer who have received at least one preceding treatment regimen for advanced disease.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
